Clinical trials: Renal Impairment
Acute Renal Failure
Safety Study of a Selective Cytopheretic Device (SCD) in Patients With Acute Renal Failure
The purpose of this protocol is to evaluate the safety of a selective cytopheretic device (SCD) in patients that are on continuous renal replacement therapy (CRRT) for acute renal failure (ARF).
- Trial name
- NCT01072682
- Testing
- Selective cytopheretic device (SCD)
- Where
- 7 sites in United States
- Volunteers
- 35 people
- Sponsor
- SeaStar Medical
Chronic Kidney Disease, Cardiovascular Disease
Mechanisms of Chronic Kidney Disease (CKD)-Induced Foam Cell Formation
There is currently little understanding of macrophage cholesterol homeostasis and foam cell formation across the spectrum of CKD.
- Trial name
- NCT01671605
- Where
- United States
- Volunteers
- 103 people
- Sponsor
- Vanderbilt University Medical Center
Renal Insufficiency, Diabetes Mellitus
Renal Effects of Two Iodinated Contrast Media in Patients at Risk Undergoing Computed Tomography
It is well known that X-ray contrast media can affect kidney function in some patients, especially when administered intra-arterially, and patients who already suffer from reduced kidney function and diabetes mellitus may be at…
- Trial name
- NCT00209417
- Testing
- Iodixanol 320-Arm 1, Iopamidol 300-Arm 2
- Where
- 2 sites in United States, United Kingdom
- Volunteers
- 656 people
- Sponsor
- GE Healthcare
Infection, Heart Failure
Rural Home Hospital: Proof of Concept
This study examines the implications of providing hospital-level care in rural homes.
- Conditions
- Infection, Heart Failure, Chronic Obstructive Pulmonary Disease, Asthma
- Trial name
- NCT04531280
- Testing
- Home hospital care
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Brigham and Women's Hospital
Fabry Disease, Chronic Kidney Disease, Stage IV (Severe)
Severe Renal Disease Study in Fabry Patients Treated With Fabrazyme
This study was designed to determine appropriate treatment with Fabrazyme at a biweekly dose of either 1 mg/kg or 3 mg/kg in a population of patients with severe renal disease burden.
- Trial name
- NCT00837824
- Testing
- Fabrazyme (agalsidase beta)
- Where
- 9 sites in United States
- Volunteers
- 20 people
- Sponsor
- Genzyme, a Sanofi Company
Renal Insufficiency, Chronic, Kidney Disease, Chronic
A Study of LY2928057 in Hemodialysis Participants
This study will evaluate the safety of LY2928057 and how LY2928057 affects hemoglobin in hemodialysis participants. This study will involve multiple doses of LY2928057 given during a 6 week period either after a participant…
- Trial name
- NCT01991483
- Testing
- LY2928057
- Where
- 4 sites in United States
- Volunteers
- 28 people
- Sponsor
- Eli Lilly and Company
End Stage Renal Disease, Chronic Kidney Diseases
Berinert (C1INH) vs Placebo for DGF/IRI
This is a Phase I/II double-blind, randomized, placebo-controlled study assessing safety and limited efficacy of intraoperative C1INH (500U/kidney) vs.
- Trial name
- NCT04696146
- Testing
- Berinert
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Cedars-Sinai Medical Center
Chronic Kidney Disease (CKD)
A Phase 3b Study of Erythropoietin Drugs Using a Specified Dosing Algorithm in Patients With Chronic Kidney Disease on Hemodialysis
A phase 3b study for subjects receiving Epogen to compare a dosing algorithm between Hospira Epoetin and Standard of Care Epogen.
- Trial name
- NCT02504294
- Testing
- Epoetin Hospira Arm, Standard of Care Arm, IV Iron
- Where
- 45 sites in United States, Puerto Rico
- Volunteers
- 432 people
- Sponsor
- Pfizer
Acute Renal Failure, Kidney Disease
Prevention of Serious Adverse Events Following Angiography
The purpose of this research study is to compare the effectiveness of intravenous isotonic sodium bicarbonate with intravenous isotonic sodium chloride and oral N-acetylcysteine (NAC) with oral placebo for the prevention of…
- Conditions
- Acute Renal Failure, Kidney Disease, Coronary Artery Disease
- Trial name
- PRESERVE (NCT01467466)
- Testing
- IV isotonic saline, IV isotonic bicarbonate, N-acetylcysteine
- Where
- 54 sites in United States, Australia and 2 more
- Volunteers
- 5,177 people
- Sponsor
- VA Office of Research and Development
Complications Wounds, Negative Pressure Wound Therapy
Incisional Negative Pressure Wound Therapy in High Risk Patients Undergoing Panniculectomy: A Prospective Randomized Controlled Trial
Incisional negative pressure therapy (INPWT) has previously been shown in certain patient populations to decrease wound healing complications, decrease the rate of hematomas and seromas, as well as have better scar quality.
- Conditions
- Complications Wounds, Negative Pressure Wound Therapy, Wound Healing Delayed, Incisional
- Trial name
- NCT03010137
- Testing
- Incisional Negative Pressure Wound Therapy, Standard Closure with Skin Glue, PICO (Smith&Nephew)
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University of California, Davis
Chronic Kidney Disease, Hyperparathyroidism, Secondary
Safety and Efficacy of CTAP101 to Treat Secondary Hyperparathyroidism in Stage 3 or 4 CKD and Vitamin D Insufficiency
This study will evaluate the efficacy of CTAP101 Capsules versus placebo in reducing intact parathyroid hormone (iPTH) by at least 30% from pretreatment baseline; safety and tolerability of CTAP101 will also be evaluated
- Conditions
- Chronic Kidney Disease, Hyperparathyroidism, Secondary, Vitamin D Deficiency
- Trial name
- NCT01704079
- Testing
- CTAP101 30 μg capsules, Sugar pill to CTAP101 30 μg capsules
- Where
- United States
- Volunteers
- 216 people
- Sponsor
- OPKO IP Holdings II, Inc.
Type 2 Diabetes Mellitus
Specified Drug-Use Survey of Trelagliptin Tablets "Survey on Long-term Use in Type 2 Diabetes Mellitus Patients With Severe Renal Impairment or End-stage Renal Disease"
The purpose of this study is to evaluate the long-term safety of trelagliptin tablets in patients with type 2 diabetes mellitus complicated by severe renal impairment or end-stage renal failure in the routine clinical setting.
- Trial name
- NCT04285983
- Testing
- Trelagliptin
- Where
- Japan
- Volunteers
- 89 people
- Sponsor
- Takeda
Anemia in Chronic Kidney Disease Patients Not on Dialysis
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
A phase 3, multicenter, randomized, double-blind, parallel group study. Anemic subjects with chronic kidney disease (CKD) and not on dialysis will be randomized 1:1 to 1 of 2 dosing strategies to evaluate the proportion of…
- Trial name
- START-CKD (NCT01652872)
- Testing
- Darbepoetin alfa
- Where
- 249 sites in United States, Puerto Rico
- Volunteers
- 756 people
- Sponsor
- Amgen
Chronic Kidney Disease
Study to Compare Palindrome vs. BioFlo DuraMax Dialysis Catheters
Numerous catheter designs have been studied to increase efficacy and minimize complications of catheter hemodialysis. Major complications of catheters include thrombosis, central venous stenosis, infection, and dialysis…
- Trial name
- NCT02796300
- Testing
- Bioflo Dialysis Catheter, Palindrome Dialysis Catheter
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- University of California, Los Angeles
Kidney Disease, End-Stage
Electronic Patient-Reported Outcomes in Clinical Kidney Practice (ePRO Kidney)
People living with end-stage kidney disease (ESKD) need dialysis or transplantation in order to stay alive. This illness and treatment significantly impact peoples' health, emotions, work and relationships.
- Trial name
- NCT03149328
- Testing
- Educational Support
- Where
- 2 sites in Canada
- Volunteers
- 594 people, healthy volunteers welcome
- Sponsor
- University of Alberta
Renal Insufficiency, Chronic
Study to Evaluate the Pharmacokinetics and Pharmacodynamics of Dabigatran Etexilate in Patients With Stable Severe Renal Disease.
The study to be conducted is a prospective, open label trial. It is designed to evaluate the pharmacokinetic/pharmacodynamic and coagulation parameters and safety of dabigatran etexilate in patients with chronic kidney disease.
- Trial name
- NCT01711853
- Testing
- Dabigatran Etexilate
- Where
- Netherlands
- Volunteers
- 19 people
- Sponsor
- Boehringer Ingelheim
Bleeding Disorder, Stroke, Ischemic
XIENCE 28 Global Study
XIENCE 28 Global Study is a prospective, single arm, multi-center, open label, non-randomized trial to further evaluate the safety of 1-month (as short as 28 days) dual antiplatelet therapy (DAPT) in subjects at high risk of…
- Conditions
- Bleeding Disorder, Stroke, Ischemic, Stroke Hemorrhagic, Hematological Disease
- Trial name
- NCT03355742
- Testing
- XIENCE, DAPT
- Where
- 52 sites in Austria, Belgium and 11 more
- Volunteers
- 963 people
- Sponsor
- Abbott Medical Devices
Renal Failure
Multicenter, Prospective, Rand, PK Study of LCP-Tacro™ Compared to Prograf® Capsules in De Novo Adult Kidney Transplant
The purpose of this study is to evaluate the pharmacokinetics of LCP-Tacro tablets administered once-daily compared to Prograf capsules administered twice-daily after kidney transplantation.
- Trial name
- NCT01666951
- Testing
- LCP-Tacro tablets, Prograf
- Where
- 13 sites in United States
- Volunteers
- 36 people
- Sponsor
- Veloxis Pharmaceuticals
Diabetes Mellitus, Type 2
Safety and Efficacy in Type 2 Diabetic Patients With Severe Chronic Renal Impairment, 5 mg BI 1356 (Linagliptin) vs. Placebo, Insulin Background Inclusive
to determine safety, efficacy and tolerability of BI 1356 versus placebo
- Trial name
- NCT00800683
- Testing
- BI 1356
- Where
- 53 sites in United States, Australia and 4 more
- Volunteers
- 133 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2
A Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease
The researchers are doing this study to see if semaglutide can slow down the growth and worsening of chronic kidney disease in people with type 2 diabetes.
- Trial name
- FLOW (NCT03819153)
- Testing
- Semaglutide
- Where
- 413 sites in United States, Argentina and 26 more
- Volunteers
- 3,533 people
- Sponsor
- Novo Nordisk A/S
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.